Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study

BACKGROUND: In the prepertuzumab era, we evaluated the clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who underwent first-line trastuzumab-based or lapatinib-based therapy according to prior exposure to (neo)adjuvant trastuzumab....

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:ESMO Open
Päätekijät: Blondeaux, Eva, Ferreira, Arlindo R, Poggio, Francesca, Puglisi, Fabio, Bighin, Claudia, Sottotetti, Federico, Montemurro, Filippo, Poletto, Elena, Lai, Antonella, Sini, Valentina, Minuti, Gabriele, Mura, Silvia, Fontana, Andrea, Fregatti, Piero, Cardinali, Barbara, Lambertini, Matteo, Del Mastro, Lucia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7437709/
https://ncbi.nlm.nih.gov/pubmed/32817059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000719
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia